• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy
• Books
• Gallery

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi, Aug. 11 Ranbaxy Laboratories Ltd has received final approval from the US Food and Drug Administration to manufacture and market Sumatriptan Succinate tablets, which is indicated for the acute treatment of migraine attacks in adults.

“The Office of Generic Drugs, US Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Imitrex by GlaxoSmithKline. The total annual market sales for Sumatriptan Succinate 25 mg and 50 mg tablets were $379 million,” said a press statement.

“This product will be launched immediately to all classes of trade and further expands our product portfolio of affordable generic product formulations,” according to Mr Bill Winter, Vice-President, Trade Sales, North America.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line